# Celgene clinical trials: 428 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 428 trials with Celgene as lead sponsor, 10 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Celgene: 428 rows for $21.40, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/celgene

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 428
- Recruiting or not yet: 10
- Read on: November 19, 2026

## Trials

The 25 newest of 428, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 23, 2026 | NCT07837115 | A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of... | Celgene | Phase 1 | Recruiting | Healthy Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837115) |
| July 14, 2026 | NCT07700329 | A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese Participants | Celgene | Phase 1 | Not yet recruiting | Healthy Volunteers | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07700329) |
| November 21, 2025 | NCT07242781 | A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants | Celgene | Phase 1 | Terminated | Healthy Volunteers | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07242781) |
| May 25, 2025 | NCT06988488 | A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With... | Celgene | Phase 1/2 | Recruiting | Multiple Myeloma | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06988488) |
| April 4, 2025 | NCT06911502 | A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in... | Celgene | Phase 3 | Recruiting | Follicular Lymphoma | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06911502) |
| February 5, 2025 | NCT06808984 | Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's... | Celgene | Phase 2 | Recruiting | Agitation, Alzheimer Disease | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06808984) |
| January 20, 2025 | NCT06782490 | A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | Celgene | Phase 2 | Recruiting | Multiple Sclerosis Spasticity | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06782490) |
| January 8, 2025 | NCT06764485 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic... | Celgene | Phase 3 | Active not recruiting | Metastatic Castration-resistant Prostate Cancer | 960 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06764485) |
| August 2, 2024 | NCT06535399 | Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of... | Celgene | Phase 1 | Completed | Hepatic Impairment, Healthy Volunteers | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06535399) |
| May 29, 2024 | NCT06433505 | A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants | Celgene | Phase 1 | Completed | Healthy Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06433505) |
| May 22, 2024 | NCT06425302 | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced... | Celgene | Phase 2 | Active not recruiting | Lymphoma, Follicular | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06425302) |
| May 16, 2024 | NCT06417229 | Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants | Celgene | Phase 1 | Completed | Healthy Participants | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06417229) |
| May 13, 2024 | NCT06411730 | A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly... | Celgene | Phase 1 | Completed | Healthy Participants | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06411730) |
| April 12, 2024 | NCT06363630 | A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of... | Celgene | Phase 1 | Completed | Healthy Volunteers | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06363630) |
| April 10, 2024 | NCT06356129 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated... | Celgene | Phase 3 | Active not recruiting | Large B-cell Lymphoma | 850 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06356129) |
| March 19, 2024 | NCT06318676 | A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment | Celgene | Phase 1 | Completed | Renal Impairment | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06318676) |
| January 31, 2024 | NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory... | Celgene | Phase 3 | Withdrawn | Multiple Myeloma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06232707) |
| January 29, 2024 | NCT06227975 | A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered \[14C\]-BMS-986368 in Healthy Male Participants | Celgene | Phase 1 | Completed | Healthy Volunteers | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06227975) |
| December 14, 2023 | NCT06170723 | A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants | Celgene | Phase 1 | Completed | Healthy Participants | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06170723) |
| December 11, 2023 | NCT06163898 | A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma | Celgene | Phase 1 | Terminated | Multiple Myeloma | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06163898) |
| September 21, 2023 | NCT06045806 | A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance... | Celgene | Phase 3 | Active not recruiting | Multiple Myeloma | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06045806) |
| August 29, 2022 | NCT05519085 | A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in... | Celgene | Phase 3 | Recruiting | Relapsed or Refractory Multiple Myeloma | 810 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05519085) |
| January 31, 2022 | NCT05214768 | A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis | Celgene | Phase 3 | Completed | Eosinophilic Gastroenteritis | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05214768) |
| January 3, 2022 | NCT05175352 | A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving... | Celgene | Phase 1 | Completed | Eosinophilic Esophagitis | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05175352) |
| October 29, 2021 | NCT05099822 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants | Celgene | Phase 1 | Terminated | Healthy Volunteers | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05099822) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 161 |
| Phase 1/2 | 30 |
| Phase 2 | 96 |
| Phase 2/3 | 5 |
| Phase 3 | 71 |
| Phase 4 | 2 |
| Not applicable | 10 |
| Observational | 53 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 313 |
| Terminated | 75 |
| Active not recruiting | 13 |
| Recruiting | 9 |
| Withdrawn | 7 |
| No longer available | 5 |
| Approved for marketing | 2 |
| Available | 2 |
| Unknown | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Multiple Myeloma | 92 |
| Recurrence | 53 |
| Myelodysplastic Syndromes | 45 |
| Leukemia, Myeloid, Acute | 29 |
| Lymphoma | 27 |
| Lymphoma, Non-Hodgkin | 27 |
| Neoplasms | 22 |
| Carcinoma, Non-Small-Cell Lung | 15 |
| Lymphoma, Follicular | 14 |
| Pancreatic Neoplasms | 14 |
| Leukemia | 14 |
| Breast Neoplasms | 14 |
| Lymphoma, Large B-Cell, Diffuse | 13 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 12 |
| Crohn Disease | 10 |
| Melanoma | 9 |
| Neoplasm Metastasis | 9 |
| Renal Insufficiency | 9 |
| Anemia | 9 |
| Lymphoma, Mantle-Cell | 8 |
| beta-Thalassemia | 8 |
| Hematologic Neoplasms | 8 |
| Glioblastoma | 8 |
| Prostatic Neoplasms | 8 |
| Primary Myelofibrosis | 8 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Glass companies in the United States](https://specstream.ai/data/businesses/glass-companies/united-states)
- [Pediatric endocrinology practices in the United States](https://specstream.ai/data/businesses/pediatric-endocrinology-practices/united-states)
- [Video production companies in the United States](https://specstream.ai/data/businesses/video-production-companies/united-states)
- [Coffee shops in the United States](https://specstream.ai/data/businesses/coffee-shops/united-states)
- [Hydraulic repair companies in the United States](https://specstream.ai/data/businesses/hydraulic-repair-companies/united-states)
- [Product design firms in the United States](https://specstream.ai/data/businesses/product-design-firms/united-states)
